
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity
Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Financing
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Sunstone Life Science Ventures
Deal Size : $11.0 million
Deal Type : Series A Financing
Resalis Raises Series A to Complete First Clinical Trial for RES-010 in Obesity
Details : The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program RES-010, a non-coding RNA-based compound, in obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Sunstone Life Science Ventures
Deal Size : $11.0 million
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Claris Ventures
Deal Size : $10.6 million
Deal Type : Financing
Details : The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Claris Ventures
Deal Size : $10.6 million
Deal Type : Financing
